BIOLASE (BIOL) Competitors

BIOLASE (NASDAQ:BIOL) and Avinger (NASDAQ:AVGR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Do institutionals and insiders have more ownership in BIOL or AVGR?

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 18.3% of Avinger shares are held by institutional investors. 0.3% of BIOLASE shares are held by company insiders. Comparatively, 42.8% of Avinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, BIOL or AVGR?

BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Avinger has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Is BIOL or AVGR more profitable?

BIOLASE has a net margin of -41.65% compared to Avinger's net margin of -261.06%. BIOLASE's return on equity of -1,782.73% beat Avinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Avinger	-261.06%	-5,527.11%	-123.25%

Does the media prefer BIOL or AVGR?

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Avinger'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Avinger	Neutral

Do analysts prefer BIOL or AVGR?

BIOLASE presently has a consensus price target of $1.20, indicating a potential upside of 11,167.61%. Given BIOLASE's stronger consensus rating and higher probable upside, research analysts clearly believe BIOLASE is more favorable than Avinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avinger	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has higher valuation and earnings, BIOL or AVGR?

Avinger has lower revenue, but higher earnings than BIOLASE. Avinger is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.01	-$20.63M	-$14.94	0.00
Avinger	$7.65M	0.21	-$18.32M	-$11.06	-0.04

Summary

BIOLASE beats Avinger on 8 of the 14 factors compared between the two stocks.